AR and non-Hodgkin lymphoma: Of note, EBER+ AR‐NHL demonstrated inferior survival compared to patients with EBER− AR‐NHL, with a hazard ratio for death of 3.872 (95% CI: 1.073–13.974, p = 0.026, Figure 1B).